Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jun;5(6):431-437.
doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30.

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

Affiliations
Meta-Analysis

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials

Sophia Zoungas et al. Lancet Diabetes Endocrinol. 2017 Jun.

Abstract

Background: Intensive glucose control is understood to prevent complications in adults with type 2 diabetes. We aimed to more precisely estimate the effects of more intensive glucose control, compared with less intensive glucose control, on the risk of microvascular events.

Methods: In this meta-analysis, we obtained de-identified individual participant data from large-scale randomised controlled trials assessing the effects of more intensive glucose control versus less intensive glucose control in adults with type 2 diabetes, with at least 1000 patient-years of follow-up in each treatment group and a minimum of 2 years average follow-up on randomised treatment. The prespecified and standardised primary outcomes were kidney events (a composite of end-stage kidney disease, renal death, development of an estimated glomerular filtration rate <30 mL/min per 1·73m2, or development of overt diabetic nephropathy), eye events (a composite of requirement for retinal photocoagulation therapy or vitrectomy, development of proliferative retinopathy, or progression of diabetic retinopathy), and nerve events (a composite of new loss of vibratory sensation, ankle reflexes, or light touch). We used a random-effects model to calculate overall estimates of effect.

Findings: We included four trials (ACCORD, ADVANCE, UKPDS, and VADT) with 27 049 participants. 1626 kidney events, 795 eye events, and 7598 nerve events were recorded during the follow-up period (median 5·0 years, IQR 4·5-5·0). Compared with less intensive glucose control, more intensive glucose control resulted in an absolute difference of -0·90% (95% CI -1·22 to -0·58) in mean HbA1c at completion of follow-up. The relative risk was reduced by 20% for kidney events (hazard ratio 0·80, 95% CI 0·72 to 0·88; p<0·0001) and by 13% for eye events (0·87, 0·76 to 1·00; p=0·04), but was not reduced for nerve events (0·98, 0·87 to 1·09; p=0·68).

Interpretation: More intensive glucose control over 5 years reduced both kidney and eye events. Glucose lowering remains important for the prevention of long-term microvascular complications in adults with type 2 diabetes.

Funding: None.

PubMed Disclaimer

Comment in

  • Tightening our understanding of intensive glycaemic control.
    Herrington WG, Preiss D. Herrington WG, et al. Lancet Diabetes Endocrinol. 2017 Jun;5(6):405-407. doi: 10.1016/S2213-8587(17)30095-5. Epub 2017 Mar 30. Lancet Diabetes Endocrinol. 2017. PMID: 28365412 No abstract available.
  • Microvascular outcomes in type 2 diabetes.
    Stehouwer CDA, van Sloten TT. Stehouwer CDA, et al. Lancet Diabetes Endocrinol. 2017 Aug;5(8):579. doi: 10.1016/S2213-8587(17)30187-0. Lancet Diabetes Endocrinol. 2017. PMID: 28732662 No abstract available.
  • Microvascular outcomes in type 2 diabetes - Authors' reply.
    Zoungas S, Gerstein HC, Holman RR, Reaven P, Woodward M, Arima H, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) writing group. Zoungas S, et al. Lancet Diabetes Endocrinol. 2017 Aug;5(8):580. doi: 10.1016/S2213-8587(17)30185-7. Lancet Diabetes Endocrinol. 2017. PMID: 28732664 No abstract available.

Publication types

MeSH terms